This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Novo Nordisk A/s. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Andrew Mark Louw: Innovator in GLP-1 Compositions
Introduction
Andrew Mark Louw is a notable inventor based in Vaerloese, Denmark. He has made significant contributions to the field of pharmaceuticals, particularly in the development of GLP-1 compositions. His work is essential in advancing treatments for various health conditions.
Latest Patents
Louw holds a patent for "GLP-1 compositions and uses thereof." This invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide, which comprises no more than 0.1% (w/w) phenol and above 6.4 mg/ml sodium chloride. The patent also covers their preparation, kits comprising such compositions, and their various uses. He has 1 patent to his name.
Career Highlights
Andrew Mark Louw is associated with Novo Nordisk A/S, a leading global healthcare company. His role at Novo Nordisk allows him to contribute to innovative solutions in diabetes care and other chronic conditions. His expertise in pharmaceutical compositions has positioned him as a valuable asset in the industry.
Collaborations
Louw has collaborated with notable colleagues, including Dorthe Kot Engelund and Soeren Snitker. These partnerships enhance the research and development efforts at Novo Nordisk, fostering innovation in the pharmaceutical sector.
Conclusion
Andrew Mark Louw is a distinguished inventor whose work in GLP-1 compositions has the potential to impact healthcare significantly. His contributions to Novo Nordisk and the pharmaceutical field exemplify the importance of innovation in improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile